Researchers of a phase 2 trial, conducted in China, showed that the PD-L1 x VEGF bispecific antibody IMM2510 (AXN-2510), when combined with chemotherapy, achieved promising results as a frontline treatment for advanced non–small cell lung cancer (NSCLC). Among patients who were efficacy-evaluable, the overall response rate was 62%, consisting entirely of partial responses. Response rates were particularly strong in patients with squamous NSCLC (80%) compared with nonsquamous disease (46%). Importantly, no dose-limiting toxicities were observed, and treatment-related adverse events were mostly manageable and consistent with VEGF inhibition, such as hypertension, proteinuria, and hemoptysis, while immune-related toxicities were infrequent and mild.
The ongoing trial is enrolling patients with EGFR wild-type NSCLC without ALK or ROS1 fusions and excluding those who have had prior PD-1, PD-L1, or VEGF therapies, uncontrolled chronic illness, or active infections. Participants receive IMM2510 in combination with chemotherapy regimens tailored to either squamous or nonsquamous NSCLC. With no treatment-related deaths or serious safety concerns, the early results suggest IMM2510 could be a promising candidate to advance into phase 3 trials. Investigators and company leadership believe the bispecific class has the potential to redefine the standard of care in frontline NSCLC and possibly extend to other indications in the future.
Reference: Ryan C. Frontline IMM2510 Plus Chemo Drives Responses in Advanced NSCLC. OncLive. Published July 31, 2025. Accessed August 19, 2025. https://www.onclive.com/view/frontline-imm2510-plus-chemo-drives-responses-in-advanced-nsclc
Link: https://www.onclive.com/view/frontline-imm2510-plus-chemo-drives-responses-in-advanced-nsclc
